Cardioprotective Effects of Pioglitazone in Type 2 Diabetes
| Autor: | Carolina Solis-Herrera, Robert E.J. Ryder, Devjit Tripathy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
From Research To Practice
Drug medicine.drug_class business.industry Endocrinology Diabetes and Metabolism media_common.quotation_subject Type 2 diabetes Pharmacology medicine.disease Insulin resistance Diabetes mellitus Internal Medicine medicine Thiazolidinedione Adverse effect business Pioglitazone medicine.drug media_common Glycemic |
| Zdroj: | Diabetes Spectr |
| ISSN: | 1944-7353 1040-9165 |
| Popis: | Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium–glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|